Articles from Moleculent AB

Moleculent AB, the life sciences technology company pioneering functional profiling, today announced Glimt, an automated platform that detects cell-cell interactions directly in formalin-fixed, paraffin-embedded (FFPE) tissue. The Glimt platform is now available to selected academic and biopharma labs through the Moleculent early access program, with commercial shipments expected in 2027.

Moleculent AB, a life sciences technology company pioneering functional profiling to map cell-cell communication at scale in human tissue, today announced the closing of a $20 million financing round. Led by Rubicon Healthcare Partners, with participation from ARCH Venture Partners, Eir Ventures, and other existing investors, the new capital will support expansion of the company’s Techstart Early Access Program, accelerate commercial operations in the United States, and drive the commercial launch of the instrument.

Moleculent AB, a company pioneering technology to study how cells communicate, today announced the launch of its Techstart early access program. Through this program, selected translational researchers can access the company’s novel platform to enable the high-plex functional profiling of cell-cell interactions directly in FFPE tissue samples.

Moleculent AB, a company pioneering technology to study the communication between cells in human tissue, today announced the closing of its oversubscribed $26 million Series A financing. The round was led by ARCH Venture Partners (ARCH) and co-led by Eir Ventures with participation from the company’s existing investors. ARCH’s Patrick Weiss has been appointed Chairman. Sean Kendall from ARCH, together with Magnus Persson from Eir Ventures, have also joined the company’s Board of Directors.